Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Epidemiology ; (12): 673-676, 2023.
Article in Chinese | WPRIM | ID: wpr-985545

ABSTRACT

With the expansion of mpox virus infection from endemic to a global epidemic in 2022, the WHO declared that the mpox event constituted a Public Health Emergency of International Concern. Due to the high degree of gene sequence similarity among orthopox viruses and cross-reactive antibodies induced by orthoviruses, smallpox vaccination may affect the immune response induced by mpox virus infection. The analysis of the protective effects of smallpox vaccination against mpox virus infection will help define the focus of prevention and control. In this review, we clarify the protection of the smallpox vaccine against mpox virus infection by analyzing the correlation between smallpox vaccination, immune response status, and clinical data and providing evidence for the prevention, control, and strategies of mpox epidemics.


Subject(s)
Humans , Smallpox/epidemiology , Monkeypox/drug therapy , Smallpox Vaccine/therapeutic use , Vaccination , Immunity
2.
Chinese Journal of Preventive Medicine ; (12): 70-77, 2023.
Article in Chinese | WPRIM | ID: wpr-969846

ABSTRACT

Human respiratory syncytial virus (HRSV) is one of the main pathogen causing severe acute lower respiratory tract infections in infants and the elderly, with high incidence rate and mortality worldwide. Vaccine is one of the important measure to prevent infection, transmission and severe disease of HRSV, but currently there is no officially approved preventive vaccine for prevention of HRSV in the world. This paper reviews and analyzes the current research and development progress of HRSV vaccine, summarizes the design routes of different types of HRSV preventive vaccines, and discusses the difficulties and challenges in vaccine research and development, in order to provide reference for the research and development of HRSV vaccine and the development of clinical trials.


Subject(s)
Infant , Humans , Aged , Respiratory Syncytial Virus, Human , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Vaccines/therapeutic use , Respiratory Tract Infections
SELECTION OF CITATIONS
SEARCH DETAIL